RT Journal Article
SR Electronic
T1 Pre-existing cardiovascular disease rather than cardiovascular risk factors drives mortality in COVID-19
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.12.02.20242933
DO 10.1101/2020.12.02.20242933
A1 Kevin O’Gallagher
A1 Anthony Shek
A1 Daniel M. Bean
A1 Rebecca Bendayan
A1 James T. H. Teo
A1 Richard J. B. Dobson
A1 Ajay M. Shah
A1 Rosita Zakeri
YR 2020
UL http://medrxiv.org/content/early/2020/12/04/2020.12.02.20242933.abstract
AB Background The association between cardiovascular (CV) risk factors, such as hypertension and diabetes, established CV disease (CVD), and susceptibility to CV complications or mortality in COVID-19 remains unclear.Methods We conducted a cohort study of consecutive adults hospitalised for severe COVID-19 between 1st March and 30th June 2020. Pre-existing CVD, CV risk factors and associations with mortality and CV complications were ascertained.Findings Among 1,721 patients (median age 71 years, 57% male), 349 (20.3%) had pre-existing CVD (CVD), 888 (51.6%) had CV risk factors without CVD (RF-CVD), 484 (28.1%) had neither. Patients with CVD were older with a higher burden of non-CV comorbidities. During follow-up, 438 (25.5%) patients died: 37% with CVD, 25.7% with RF-CVD and 16.5% with neither. CVD was independently associated with in-hospital mortality among patients <70 years of age (adjusted HR 2.43 [95%CI 1.16-5.07]), but not in those ≥70 years (aHR 1.14 [95%CI 0.77-1.69]). RF-CVD were not independently associated with mortality in either age group (<70y aHR 1.21 [95%CI 0.72-2.01], ≥70y aHR 1.07 [95%CI 0.76-1.52]). Most CV complications occurred in patients with CVD (66%) versus RF-CVD (17%) or neither (11%; p<0.001). 213 [12.4%] patients developed venous thromboembolism (VTE). CVD was not an independent predictor of VTE.Interpretation In patients hospitalised with COVID-19, pre-existing established CVD appears to be a more important contributor to mortality than CV risk factors in the absence of CVD. CVD-related hazard may be mediated, in part, by new CV complications. Optimal care and vigilance for destabilised CVD are essential in this patient group.Competing Interest StatementJTHT received research funding from Innovate UK & Office of Life Sciences, and iRhythm Technologies, and holds shares <5,000 UK pounds in Glaxo Smithkline and Biogen. The other authors declare no competing interests.Funding StatementThis work was supported in part by the British Heart Foundation (CH/1999001/11735 and RE/18/2/34213 to AMS) and the National Institute for Health Research Biomedical Research Centres (NIHR BRCs) at Guys & St Thomas NHS Foundation Trust (IS-BRC-1215-20006) and South London and Maudsley NHS Foundation Trust (SLAM; IS-BRC-1215-20018) both with Kings College London. RZ is also supported by a Kings Prize Fellowship. AMS is also supported by the Fondation Leducq. KOG is supported by a MRC Clinical Training Fellowship. AS is funded by the Kings Medical Research Trust. DMB holds a UKRI Fellowship as part of HDRUK MR/S00310X/1. RB is supported by a Medical Research Council (MRC) Skills Development Fellowship programme (MR/R016372/1) and the NIHR SLAM BRC. RJBD is also supported by Health Data Research UK (HDRUK); UK Research and Innovation (UKRI) London Medical Imaging & Artificial Intelligence Centre for Value Based Healthcare; the BigData@Heart Consortium (Grant No. 116074 of the European Union Horizon 2020 programme); the NIHR BRC and Research Informatics Unit at University College London Hospitals; and the NIHR Applied Research Collaboration South London at KCHFT. The views expressed are those of the authors and not necessarily those of NIHR or the Department of Health and Social Care. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study adhered to the principles of the UK Data Protection Act 2018 and UK National Health Service (NHS) information governance requirements and was conducted under London South East Research Ethics Committee approval (reference 12/LO/2048) granted to the Kings Electronic Records Research Interface (KERRI). Specific work on COVID-19 was reviewed with expert patient input on a virtual committee with Caldicott Guardian oversight.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe authors declare that all data supporting the findings of this study are available within the article (and its supplementary information files). Individual participant data will not be made available due to confidentiality regulations.